Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment

Autor: Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf

Publikováno v: Cancer Medicine, Vol 9, Iss 14, Pp 4991-5007 (2020)

Abstract Background Treatment of patients with solid tumors and KRAS mutations remains disappointing. One option is the combined inhibition of pathways involved in RAF‐MEK‐ERK and PI3K‐AKT‐mTOR. Methods Patients with relapsed solid tumors wer

Externí odkaz: https://doaj.org/article/04f6918ff70742839866e3f4fa056a57

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS)

Autor: Jesus Corral, E. Pereira, Anne-Marie C. Dingemans, Lukas C. Heukamp, Christian Grohé, Helge Bischoff, Enric Carcereny, Anna Kron, Masyar Gardizi, Martin Sebastian, Niki Karachaliou, Bartomeu Massuti, Egbert F. Smit, Martin Reck, Hans-Ulrich Schildhaus, Richard Riedel, Jana Fassunke, Lucia Nogova, Sabine Merkelbach-Bruse, Mariano Provencio, Sebastian Michels, Matthias Scheffler, Sacha I. Rothschild, Enriqueta Felip, Martin Hellmich, A. Insa, Jeremy Franklin, Petra Schmalz, Rafael Rosell, Andreas H. Scheel, Roopika Menon, Jürgen Wolf, Reinhard Büttner, Delvys Rodriguez-Abreu, Diana S.Y. Abdulla, Rieke Fischer, Christian Brandts, Thorsten Persigehl, Meike Limburg

Publikováno v: Journal of Thoracic Oncology, 14(7), 1266-1276. Elsevier Science
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
JOURNAL OF THORACIC ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

Introduction: ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09274df74058250ad1cc1423ee3f46f1
https://cris.maastrichtuniversity.nl/en/publications/e03b14f3-1f0d-4ea5-8e33-9e6784a04ef1

Motor, sensitive, and vegetative recovery in rats with compressive spinal-cord injury after combined treatment with erythropoietin and whole-body vibration

Autor: Paulina Dicken, Maria Eleni Manthou, Svenja Rink, Diana S.Y. Abdulla, Klaus Nohroudi, Habib Bendella, Julia Arnold, Merle Grigo, Doychin N. Angelov

Publikováno v: Restorative neurology and neuroscience. 39(2)

Background: Physical therapy with whole body vibration (WBV) following compressive spinal cord injury (SCI) in rats restores density of perisomatic synapses, improves body weight support and leads to a better bladder function. The purpose of the stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7ab0cd2d69955d6b215c4945e0af60
https://pubmed.ncbi.nlm.nih.gov/33612500

Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy

Autor: Jan Braess, Frank Ueckeroth, Diana S.Y. Abdulla, Carina Heydt, Anna-Kristina Eisert, Frank Beckers, Wolfram Meister, Hans-Joachim Kabitz, Johann Lorenzen, Monika Serke, Sabine Merkelbach-Bruse, Sebastian Michels, Jana Fassunke, Florian Kron, A. Meyer, Gabriele Wessling, Lucia Nogova, Bernhard Schaaf, Juliane Sueptitz, Matthias Scheffler, Carsten Schaepers, Sophia Koleczko, Reinhard Buettner, Clemens Schulte, Britta Kaminsky, Richard F. Riedel, Anna Kron, Stefan Krueger, Wolfgang Schulte, Joachim Lorenz, Michael Hamm, Kato Kambartel, Anne M. Schultheis, Christian Grohé, Jürgen Wolf, Lea Ruge, Jutta Kappes, Jens Panse, Niels Reinmuth, Rieke Fischer

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(4)

Robust data on the outcome of MET-aberrant NSCLC with nontargeted therapies are limited, especially in consideration of the heterogeneity of MET-amplified tumors (METamp).A total of 337 tumor specimens of patients with MET-altered Union for Internati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc23f7e85f05f773a1ed2d4bef0e7c16
https://pubmed.ncbi.nlm.nih.gov/33781436

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations

Autor: Winfried Randerath, Jens Kern, Jana Fassunke, Sabine Merkelbach-Bruse, Sebastian Michels, Cornelia von Levetzow, Matthias Scheffler, Anna Kron, Jürgen Wolf, Reinhard Büttner, Rieke Fischer, Alessandra Holzem, Karl-Otto Kambartel, Claudia Wompner, Britta Kaminsky, Theresa Westphal, Lucia Nogova, Jan-Philipp Weber, Richard F. Riedel, Diana S.Y. Abdulla, Elisabeth Bitter, Michaela Angelika Ihle, Sophia Koleczko, Ulrich Gerigk

Publikováno v: Lung cancer (Amsterdam, Netherlands). 144

Background MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive from known driver mutations. Activation of the MEK1-cascade is considered pivotal in resistance to targeted therapy approaches, and MAP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a076f188544b28df91c4987d96ec8628
https://pubmed.ncbi.nlm.nih.gov/32361034